Gerald J. Fetterly

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Monica Mita, Alain C. Mita, Quincy S. Chu et al. · Journal of Clinical Oncology · 2008 · 271 citations · Full text

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand et al. · Clinical Cancer Research · 2017 · 171 citations

Pharmacokinetics of paclitaxel-containing liposomes in rats

Gerald J. Fetterly, Robert M. Straubinger · AAPS PharmSci · 2003 · 111 citations · Full text

Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)

Michael Smolinski, Yahao Bu, James L. Clements et al. · Journal of Medicinal Chemistry · 2018 · 97 citations · Full text

Chemoprevention Strategy, Action Src Signaling, Molecular Biology +24

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer

Emmanuel S. Antonarakis, Elisabeth I. Heath, Edwin M. Posadas et al. · Cancer Chemotherapy and Pharmacology · 2013 · 75 citations · Full text

Src Kinase, Urology, Genitourinary Cancer +8